• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by PRA Health Sciences, Inc.

    7/1/21 9:42:54 AM ET
    $PRAH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PRAH alert in real time by email
    S-8 POS 1 nt10026444_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on July 1, 2021

    Registration No. 333-238694
    Registration No. 333-225313
    Registration No. 333-221259
    Registration No. 333-200160

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-238694
    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-225313
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-221259
    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-200160

    UNDER
    THE SECURITIES ACT OF 1933



    PRA Health Sciences, Inc.
    (Exact name of registrant as specified in its charter)

    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    46-3640387
    (I.R.S. employer identification no.)

    4130 ParkLake Avenue
    Suite 400
    Raleigh, NC 27612
    (919) 786-8200
    (Address of principal executive offices)

    PRA Health Sciences Inc. 2020 Stock Incentive Plan
    PRA Health Sciences Inc. 2018 Stock Incentive Plan
    2017 Employee Stock Purchase Plan
    PRA Health Sciences Inc. 2014 Omnibus Incentive Plan
    2013 Stock Incentive Plan For Key Employees Of PRA Health Sciences, Inc. and its Subsidiaries
    PRA Holdings, Inc. Equity Incentive Plan
    PRA International 2004 Incentive Award Plan
    Research Pharmaceutical Services, Inc. 2007 Equity Incentive Plan
    Research Pharmaceutical Services, Inc. 2002 Equity Incentive Plan
    (Full title of the plan(s))



    PRA Health Sciences, Inc.
    4130 ParkLake Avenue
    Suite 400
    Raleigh, NC 27612
    (Name and address of agent for service)

    (919) 786-8200
    (Telephone number, including area code, of agent for service)



    Copies to:

    William M. Hartnett
    Kimberly C. Petillo-Décossard
    Ross E. Sturman
    Cahill Gordon & Reindel LLP
    32 Old Slip
    New York, NY 10005
    (212) 701-3000



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☒
    Accelerated filer
    ☐
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
       
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐


    DEREGISTRATION OF UNSOLD SECURITIES

    PRA Health Sciences, Inc., a Delaware corporation (the “Company”), is filing these post-effective amendments (these “Post-Effective Amendments”) to the following Registration Statements on Form S-8 (the “Registration Statements”), which have been previously filed with the Securities and Exchange Commission (the “SEC”), to deregister any and all (i) shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), registered but unsold or otherwise unissued under each such Registration Statements as of the date hereof:

    1.
    Registration Statement No. 333-238694, filed with the SEC on May 26, 2020, registering 2,500,000 shares of Common Stock issuable pursuant to the PRA Health Sciences, Inc. 2020 Stock Incentive Plan;

    2.
    Registration Statement No. 333-225313, filed with the SEC on May 31, 2018, as amended on May 26, 2020, registering 2,000,000 shares of Common Stock issuable pursuant to the PRA Health Sciences, Inc. 2018 Stock Incentive Plan;

    3.
    Registration Statement No. 333-221259, filed with the SEC on November 1, 2017, registering 3,000,000 shares of Common Stock issuable pursuant to the 2017 Employee Stock Purchase Plan; and

    4.
    Registration Statement No. 333-200160, filed with the SEC on November 12, 2014, as amended on May 31, 2018, registering 10,188,260 shares of Common Stock issuable pursuant to the PRA Health Sciences, Inc. 2014 Omnibus Incentive Plan, the 2013 Stock Incentive Plan for Key Employees, the 2013 Stock Incentive Plan for Key Employees of PRA Health Sciences, Inc. and its Subsidiaries, the PRA Holdings, Inc. Equity Incentive Plan, PRA International 2004 Incentive Award Plan, the Research Pharmaceutical Services, Inc. 2007 Equity Incentive Plan, and the Research Pharmaceutical Services, Inc. 2002 Equity Incentive Plan.

    On February 24, 2021, the Company entered into an Agreement and Plan of Merger (as it may be amended from time to time) (the “Merger Agreement”) with ICON plc (“ICON”), ICON US Holdings Inc., a wholly owned subsidiary of ICON (“US HoldCo”), and Indigo Merger Sub, Inc., a wholly owned subsidiary of ICON and US HoldCo (“Merger Sub”), providing for, among other things, the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger as a subsidiary of ICON and US HoldCo. The Merger became effective on July 1, 2021, upon the filing of the certificate of merger with the Secretary of State of the State of Delaware.

    As a result of the Merger, the Company has terminated all offerings of its Common Stock pursuant to the Registration Statements.  In accordance with an undertaking made by the Company in the Registration Statements to remove from registration, by means of these Post-Effective Amendments, any Common Stock that had been registered but remain unsold at the termination of the offering, the Company hereby amends the Registration Statements to remove from registration all shares of Common Stock registered under the Registration Statements that remain unsold as of the date of these Post-Effective Amendments.

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in Raleigh, North Carolina on this 1st day of July, 2021.

     
    PRA HEALTH SCIENCES, INC.
       
     
    By:
    /s/ Brendan Brennan
       
    Brendan Brennan
       
    Chief Financial Officer

    No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.


    Get the next $PRAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRAH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:29:52 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:26:22 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 5:47:14 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PRA Health Sciences, Inc.

      SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 4:27:12 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 10:21:51 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      4/12/21 2:07:51 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    SEC Filings

    See more
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:48:41 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:45:04 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:47:14 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Leadership Updates

    Live Leadership Updates

    See more
    • Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

      Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in

      5/26/21 7:00:00 AM ET
      $AVXL
      $TMDX
      $PRAH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Commercial Physical & Biological Resarch

    $PRAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

      Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e

      3/3/25 8:00:00 AM ET
      $AKYA
      $CMBM
      $CSCO
      $DOMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Radio And Television Broadcasting And Communications Equipment
      Technology
    • DT Midstream Set to Join S&P MidCap 400

      NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE:DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.   Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker

      6/28/21 6:07:00 PM ET
      $SPGI
      $DTE
      $ICLR
      $PRAH
      Finance: Consumer Services
      Finance
      Electric Utilities: Central
      Utilities
    • Veradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research Network

      Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and PRA Health Sciences, Inc. (NASDAQ:PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. This press re

      6/23/21 8:01:00 AM ET
      $PRAH
      $MDRX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      EDP Services
      Technology

    $PRAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PRA Health Sciences downgraded by Truist with a new price target

      Truist downgraded PRA Health Sciences from Buy to Hold and set a new price target of $175.00 from $196.00 previously

      5/10/21 7:22:17 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Credit Suisse reiterated coverage on PRA Health Sciences with a new price target

      Credit Suisse reiterated coverage of PRA Health Sciences with a rating of Outperform and set a new price target of $169.00 from $159.00 previously

      4/29/21 10:40:10 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PRA Health Sciences downgraded by Baird with a new price target

      Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00

      4/20/21 7:51:16 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care